[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
물리적 거리두기 실천
스폰서배너광고 안내  배너1 배너2 배너3 배너4
LABox-과학으로 본 코로나19 (COVID-19)
전체보기 한빛사논문 상위피인용논문 인터뷰 그이후 한빛사통계
이근욱
이근욱 (Keun-Wook Lee) 저자 이메일 보기
분당서울대학교병원, The University of Texas MD Anderson Cancer Center
저자CV 보기
167 KB
 
조회 1416  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients
열기 Authors and Affiliations

Abstract
Purpose: Activation of YAP1, a novel oncogene in the Hippo pathway, has been observed in many cancers, including colorectal cancer. We investigated whether activation of YAP1 is significantly associated with prognosis or treatment outcomes in colorectal cancer.

Experimental Design: A gene expression signature reflecting YAP1 activation was identified in colorectal cancer cells, and patients with colorectal cancer were stratified into two groups according to this signature: activated YAP1 colorectal cancer (AYCC) or inactivated YAP1 colorectal cancer (IYCC). Stratified patients in five test cohorts were evaluated to determine the effect of the signature on colorectal cancer prognosis and response to cetuximab treatment.

Results: The activated YAP1 signature was associated with poor prognosis for colorectal cancer in four independent patient cohorts with stage I-III disease (total n = 1,028). In a multivariate analysis, the impact of the YAP1 signature on disease-free survival was independent of other clinical variables [hazard ratio (HR), 1.63; 95% confidence interval (CI), 1.25-2.13; P < 0.001]. In patients with stage IV colorectal cancer and wild-type KRAS, IYCC patients had a better disease control rate and progression-free survival (PFS) after cetuximab monotherapy than did AYCC patients; however, in patients with KRAS mutations, PFS duration after cetuximab monotherapy was not different between IYCC and AYCC patients. In multivariate analysis, the effect of YAP1 activation on PFS was independent of KRAS mutation status and other clinical variables (HR, 1.82; 95% CI, 1.05-3.16; P = 0.03).

Conclusions: Activation of YAP1 is highly associated with poor prognosis for colorectal cancer and may be useful in identifying patients with metastatic colorectal cancer resistant to cetuximab.

논문정보 F1000선정
- 형식: Research article
- 게재일: 2015년 01월 (BRIC 등록일 2017-11-14)
- 연구진: 국내(교신)+국외 연구진태극기
- 분야: Cancer Biology/Oncology
- 추천: Faculty of 1000 Biology
- 추천사유: F1000Prime Recommendations, Dissents and Comments for [Lee KW et al., Clin Cancer Res 2015, 21(2):357-64]. In F1000Prime, 17 Nov 2017; F1000Prime.com/725233286
세포 형광 이미징 멀티플렉싱을 위한 초고속 사이클링[Angew. Chem.-Int. Edit.]
고진아
발표: 고진아 (Massachusetts General Ho...)
일자: 2020년 4월 14일 (화) 오전 10시 (한국시간)
언어: 영어
참석자 접수신청하기
The presenting symptoms of cancer and stage at diagnosis[Lancet Oncol.]
구민정
발표: 구민정 (University College Londo...)
일자: 2020년 4월 20일 (월) 오후 04시 (한국시간)
언어: 영어
참석자 접수신청하기

  댓글 0
등록
 
목록
국립암센터
관련링크
이근욱 님 전체논문보기 >
관련인물
이성숙 (인제대학교 해운대백병원, T...)
이주석 (University of T...)
관련분야 논문보기
Cancer Biology/Oncology

외부링크
Google (by Keun-Wook Lee)
Pubmed (by Keun-Wook Lee)
프리미엄 Bio일정 Bio일정 프리미엄 안내
[BRIC Webinar]세포 형광 이미징 멀티플렉싱을 위한 초고속 사이클링[Angew. Chem.-Int. Edit.]
[재직자무료교육] 분석기기(HPLC) 활용 품질검사 실습(4.9~4.10) / 화장품 제형제조 기술 실습(4.13~4.14)
[재직자무료교육] 분석기기(HPLC) 활용 품질검사 실습(4.9~4.10) / 화장품 제형제조 기술 실습(4.13~4.14)
날짜: 2020.04.09~14
장소: 충청북도 청주시 흥덕구 오송읍 오송생명1로 194-41 충북산학융합본부 기업연구1관 교육장
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS
머크